Internal medicine

Virus

Entecavir

Gastroenterology

Virology

Randomized controlled trial

Lamivudine

Tenofovir

Multicenter study

Human immunodeficiency virus (HIV)

Hepatitis a virus

Chronic hepatitis

Medicine

Journal of Hepatology

Chronic hepatitis B (CHB) is the most common chronic viral infection worldwide, affecting approximately 350 million people.1 Because persistently high hepatitis B virus (HBV) replication is associated with an increased risk of compensated cirrhosis and hepatocellular carcinoma (HCC),2,3 replication-suppressing antiviral therapy is administered to patients with CHB to prevent liver-disease progression.4 As a matter of fact, oral antiviral agents, particularly entecavir (ETV), reduce the risk of long-term complications such as cirrhosis and HCC, ultimately improving survival compared to controls.

A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea